Andrey Kaprin, Chief Oncologist of Russia’s Health Ministry, discussed a personalized mRNA cancer vaccine in a radio interview. The drug will be tailored for individual patients, costing the state 300,000 rubles per case.
“On stream, when the technology is established, we should be able to get somewhere around 300 thousand rubles, I mean for the state. For patients, of course, this should be free,” he explained. The start of using the vaccine by patients is planned for early 2025.
Multiple scientific teams are collaboratively engaged in developing the drug, including the National Medical Research Center of Radiology, the Gamaleya National Research Center of Epidemiology and Microbiology, the Herzen Moscow Cancer Research Institute, and the Blokhin National Medical Research Center of Oncology. According to the National Medical Research Center of Radiology’s website, the key distinction in utilizing mRNA vaccines for cancer therapy lies in personalized methodology. By conducting a genetic analysis of each patient’s tumor, a tailored vaccine is developed to effectively “educate” the immune system to identify and attack cancer cells.
